Gilead (GILD) Form 144: Proposed 3,000-Share Sale Worth $340,710

Gilead Sciences (GILD) Form 144 notice records a proposed sale of 3,000 common shares via Morgan Stanley Smith Barney for an aggregate market value of $340,710, with an approximate sale date of 09/15/2025 on NASDAQ.

Rhea-AI Filing Summary

Gilead Sciences (GILD) Form 144 notice records a proposed sale of 3,000 common shares via Morgan Stanley Smith Barney for an aggregate market value of $340,710, with an approximate sale date of 09/15/2025 on NASDAQ. The shares were acquired as performance shares on 01/31/2024. The filing also discloses that Johanna Mercier sold 34,000 shares across three transactions in the past three months (06/16/2025, 07/15/2025, 08/15/2025) generating total gross proceeds of $3,982,524.65. The filer affirms no undisclosed material adverse information and the notice is presented as a live filing.

Positive

• Clear compliance with Rule 144 including broker, acquisition date, and past three months of sales
• Securities originated as performance shares, indicating compensation-related provenance rather than a market purchase
• Filer affirms no undisclosed material adverse information consistent with Form 144 declarations

Negative

• Insider sold 34,000 shares in the past three months, totaling $3,982,524.65, which may be viewed negatively by some investors
• Proposed sale adds supply of shares to market, albeit small relative to outstanding shares (1,240,806,916)

Insights

Financial Analyst

TL;DR: Routine insider sale of performance shares; not material to Gilead's market cap.

The notice documents a small proposed sale of 3,000 shares worth $340,710 and prior insider sales totaling 34,000 shares for $3.98 million. Relative to the reported outstanding share count of 1.2408 billion, these transactions represent de minimis dilution or supply impact. The shares were granted as performance awards, indicating compensation-related disposition rather than an operational red flag. Overall, this is a routine disclosure under Rule 144 reflecting insider liquidity activity rather than company performance.

Corporate Governance Expert

TL;DR: Compliance appears proper; disclosure of prior monthly sales is transparent and consistent with Rule 144 practice.

The filer identifies acquisition type, acquisition date, capacity of broker, and past three months of sales by the same person, which aligns with Rule 144 reporting expectations. The representation that the seller has no undisclosed material information is standard. The pattern of periodic sales from the same individual suggests scheduled or staged dispositions commonly seen with vested awards. No governance concerns are evident from the notice alone.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 filed for GILD indicate?

The Form 144 shows a proposed sale of 3,000 common shares of Gilead Sciences valued at $340,710, with an approximate sale date of 09/15/2025 on NASDAQ.

Who is the seller and what recent sales are disclosed?

The filing references sales by Johanna Mercier, who sold 34,000 shares across 06/16/2025, 07/15/2025, and 08/15/2025 for total gross proceeds of $3,982,524.65.

How were the shares being sold originally acquired?

The 3,000 shares subject to the proposed sale were acquired as performance shares on 01/31/2024 from the issuer.

Does the filing state any undisclosed material information?

By signing the notice the person represents they do not know any material adverse information about the issuer that has not been publicly disclosed.

Through which broker will the shares be sold?

The proposed sale lists Morgan Stanley Smith Barney LLC Executive Financial Services as the broker.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 09/15/2025 - 04:04 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001782135
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	GILEAD SCIENCES, INC.
SEC File Number	000-19731
Address of Issuer	333 Lakeside Drive Foster City CALIFORNIA 94404
Phone	(650) 574-3000
Name of Person for Whose Account the Securities are To Be Sold	JOHANNA MERCIER
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	3000	340710.00	1240806916	09/15/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	01/31/2024	Performance Shares	Issuer			3000	01/31/2024	Not Applicable

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
JOHANNA MERCIER 333 Lakeside Drive Foster City CA 94404	Common	08/15/2025	28000	3318924.65
JOHANNA MERCIER 333 Lakeside Drive Foster City CA 94404	Common	07/15/2025	3000	333090.00
JOHANNA MERCIER 333 Lakeside Drive Foster City CA 94404	Common	06/16/2025	3000	330510.00

144: Remarks and Signature

Remarks
Date of Notice	09/15/2025
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	02/20/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Johanna Mercier
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)